Known as the brand name migraine treatment Axert, marketed by Ortho-McNeil Pharmaceuticals, Almotriptan’s patent protection expires in May 2015. This is exciting news for research and development teams who are currently seeking to provide migraine sufferers with additional therapies. Almotriptan, or Axert, is currently FDA approved to treat migraine with or without aura in adults[…]
Almotriptan Patent to Expire in May 2015
Anti-Migraine, Drug Research & Development API, Patent Expiration 2015 Tags: migraine headachesserotonin May 05, 2015
FDA Agrees to Priority Review of Sumatriptan and Naproxen Sodium for Adolescent Patients
Anti-Migraine, Drug Research & Development API, FDA Priority Status, OTC and Compounding Product Tags: migraine headachesmigraines Apr 15, 2015
On January 15, 2015 Pernix Therapeutics excitedly announced an FDA acceptance for a priority review of Sumatriptan and Naproxen Sodium, also known as Treximet, for adolescent patients. Pernix expects an FDA approval by the second quarter of 2015, which would greatly benefit the adolescent patient population suffering from migraines. This anticipated approval would be specific[…]
Rizatriptan Gets FDA Nod as New Generic for Migraine Therapy
Anti-Inflammatory, Anti-Migraine, FDA Approved 2015 Tags: migraine headachesmigrainesserotoninUnited States Mar 12, 2015
On January 5, 2015 Jubilant Life Sciences received an FDA nod for their Rizatriptan generic formulation, paving the way for more generic forms of Merck’s blockbuster migraine medication Maxalt. The strengths approved for generic production are both 5 milligrams and 10 milligrams, which makes up an estimated 70 million dollar market. Rizatriptan is an efficacious[…]
FDA Accepts NDA for Novel Intranasal Sumatriptan to Treat Migraines
Anti-Migraine, Drug Research & Development API Tags: migraine headachesmigrainesNew Drug Application Apr 24, 2014
Exciting news was disseminated from Avanir Pharmaceuticals’ on March 28, 2014 with their announcement that the FDA had accepted a New Drug Application for their intranasal form of Sumatriptan. Designed as a novel and investigational drug-device combination product coined AVP-825, this unique form of Sumatriptan is a breath powered, intranasal form of migraine treatment. The[…]
New Guidelines Highlight Divalproex Sodium as an Effective Migraine Treatment
Anti-Migraine, Patent Expiration 2018 Tags: migraine headachesWorld Health Organization May 20, 2013
The latest news regarding divalproex sodium is exciting for patients who suffer from migraine headaches. A new set of guidelines were published in the April 24, 2012 issue of Neurology, and presented at the academy’s annual meeting in New Orleans April 21 to 28, 2013. The new guidelines are composed of information from 29 studies[…]
Zolmitriptan Is An Effective Treatment For Patients Suffering From Migraines
Anti-Migraine, Bulk Active Ingredient, OTC and Compounding Product Tags: migraine headachesmigrainesserotonin Apr 26, 2012
On November 14th, 2012 Zomig went off-patent, opening the door for generic versions of this formidable product. As an efficacious treatment for patients suffering from migraines with or without auras, zolmitriptan is also known as Zomig, marketed by AstraZeneca. Offered in both oral and orally disintegrating tablets, in 2.5 or 5 milligram tablets, zolmitriptan has[…]